Trial Profile
Phase 1 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fimepinostat (Primary) ; Rituximab; Venetoclax
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Curis
- 05 May 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results evaluating differences in transcript-level signatures of gene networks in pre-treatment tumor samples associated with future clinical response to Fimepinostat, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results (n=16; as of 1 Feb 2020) of 2 dose cohorts assessing safety and preliminary efficacy presented at the 56th Annual Meeting of the American Society of Clinical Oncology